Safety, tolerability and pharmacokinetics of dalcetrapib following single and multiple ascending doses in healthy subjects: A randomized, double-blind, placebo-controlled, Phase i study

Clinical Drug Investigation

Volumn 31, Issue 5, 2011, Pages 325-335

  Derks, Michael ^a   Anzures Cabrera, Judith ^b   Turnbull, Lynn ^b   Phelan, Mary ^b  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b NONE

Author keywords

Cholesterol ester transfer protein inhibitors; Dalcetrapib; Hyperlipidaemia; pharmacokinetics; Research and development; therapeutic use; treatment

Indexed keywords

CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; PLACEBO;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; BODY TEMPERATURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENZYME ACTIVITY; ERYTHROCYTE COUNT; FLATULENCE; GLUCOSURIA; HEART; HEART RATE; HUMAN; LABORATORY TEST; LEUKOCYTURIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; VITAL SIGN;

ADOLESCENT; ADULT; AGED; ANTICHOLESTEREMIC AGENTS; AREA UNDER CURVE; CHOLESTEROL ESTER TRANSFER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; SULFHYDRYL COMPOUNDS; TIME FACTORS; YOUNG ADULT;

EID: 79953822473     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533550-000000000-00000     Document Type: Article

References (23)

1. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005 Jan 18; 45 (2): 185-97 (Pubitemid 40094724)
2. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007 Sept 27; 357 (13): 1301-10 (Pubitemid 47481452)
3. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977 May; 62 (5): 707-14 (Pubitemid 8110784)
4. Assmann G, Schulte H, von Eckardstein A, et al. Highdensity lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and patho-physiological implications for reverse cholesterol trans-port. Atherosclerosis 1996 Jul; 124 (Suppl.): S11-20
5. Barter PJ, Brewer Jr HB, Chapman MJ, et al. Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003 Feb 1; 23 (2): 160-7 (Pubitemid 36231923)
6. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N EnglJ Med 2007 Nov 22; 357 (21): 2109-22 (Pubitemid 350146106)
7. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial. Lancet 2007 Jul 14; 370 (9582): 153-60 (Pubitemid 47042895)
8. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercho-lesterolemia. N Engl J Med 2007; 356 (16): 1620-30 (Pubitemid 46631671)
9. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007 Mar 29; 356 (13): 1304-16 (Pubitemid 46513296)
10. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre-ß-HDL formation and increases reverse cholesterol trans-port. J Lipid Res 2010 Dec; 51 (12): 3443-54
11. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomised phase II dose response study. Circulation 2002 May 7; 105 (18): 2159-65 (Pubitemid 34517159)
12. Kuivenhoven JA, de Grooth GJ, Kawamura H, et al. Effectiveness of inhibition ofcholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia. Am J Cardiol 2005 May 1; 95 (9): 1085-8 (Pubitemid 40544314)
13. Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009 Jul 1; 104 (1): 82-91
14. Kuhlmann O, Heinig K. Dalcetrapib pharmacokinetics and metabolism in the cynomolgus monkey. Xenobiotica. In press
15. International Conference on Harmonisation. E14 Clinical evaluation of QT/QTc interval prolongation and pro-arrhythmic potential for non-antiarrhythmic drugs. Oct. 2005 [online]. Available from URL: http://www.fda.gov/ RegulatoryInformation/Guidances/ucm129335. htm [Accessed 2009 Jun 1] Data on file, Roche. Report No. 1020407. Basel: July 2006
16. Derks M, Fowler S, Kuhlmann O. A single-center, openlabel, one-sequence study of dalcetrapib coadministered with ketoconazole, and an in vitro study of the S-methyl metabolite of dalcetrapib. Clin Ther 2009 Mar; 31 (3): 586-99
17. Derks M, Abt M, Mwangi A, et al. Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing. Eur J Clin Pharmacol 2010 Jun 3; 66: 775-83
18. Stein EA, Roth EM, Rhyne JM, et al. Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010 Jan; 31 (4): 480-8
19. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009 Dec; 158 (6): 896-901
20. Derks M, Fowler S, Kuhlmann O. In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates. Curr Med Res Opin 2009 Apr; 25 (4): 891-902
21. Derks M, Abt M, Phelan M, et al. Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug-drug interactions. J Clin Phar-macol 2010 Oct; 50 (10): 1188-201
22. Derks M, Abt M, Parr G, et al. No clinically relevant drug-drug interactions when dalcetrapib is coadministered with atorvastatin. Expert Opin Investig Drugs 2010 Oct; 19 (10): 1135-45
23. Derks M, Abt M, Phelan M. Lack of clinically relevant drug-drug interactions when dalcetrapib is coadministered with ezetimibe. Br J Clin Pharmacol2010 Dec; 70 (6): 825-33